These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25299626)

  • 1. [The significance of depot medication in the long-term-treatment of schizophrenia].
    Kühn KU; Wiedemann K; Hellweg R; Möller HJ
    Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].
    Breit S; Hasler G
    Nervenarzt; 2016 Jul; 87(7):719-23. PubMed ID: 26597275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.
    Leucht C; Heres S; Kane JM; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2011 Apr; 127(1-3):83-92. PubMed ID: 21257294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing antipsychotic maintenance therapy--a naturalistic study.
    Tavcar R; Dernovsek MZ; Zvan V
    Pharmacopsychiatry; 2000 Mar; 33(2):66-71. PubMed ID: 10761822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot.
    Möller HJ
    Eur Psychiatry; 2005 Aug; 20(5-6):379-85. PubMed ID: 15994065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Maintenance therapy in schizophrenia -- a brief review of the literature].
    Balla P; Frecska E
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):197-200. PubMed ID: 22987733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable antipsychotics in early psychosis: a literature review.
    Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
    Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
    Adams CE; Fenton MK; Quraishi S; David AS
    Br J Psychiatry; 2001 Oct; 179():290-9. PubMed ID: 11581108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence and the use of long-acting antipsychotics in bipolar disorder.
    El-Mallakh RS
    J Psychiatr Pract; 2007 Mar; 13(2):79-85. PubMed ID: 17414683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
    Stanković Z; Ille T
    Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.